oncnursingnews4h
Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCC
Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study
Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy ...